Literature DB >> 8712844

Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature.

S R Knowles1, L Shapiro, N H Shear.   

Abstract

BACKGROUND: Minocycline has been reported to cause serious, albeit rare, adverse events, including serum sickness-like reaction, hypersensitivity syndrome reaction, and drug-induced lupus. A retrospective review of patients seen in our Adverse Drug Reaction Clinic as well as information obtained from the Health Protection Branch was done to identify patients with minocycline-induced reactions. In addition, the literature concerning serious reactions to minocycline was reviewed. OBSERVATIONS: Six patients with a hypersensitivity syndrome reaction, 6 patients with a serum sickness-like reaction, and 1 patient who had symptoms consistent with drug-induced lupus were identified. A review of the literature identified 11 cases of hypersensitivity syndrome reaction, 1 case of serum sickness-like reaction, and 24 cases of drug-induced lupus. Serum sickness-like reactions occur sooner than hypersensitivity syndrome reactions (15.6 vs 23.7 days, P = .04). Drug-induced lupus occurs on average 2 years after the start of minocycline therapy.
CONCLUSIONS: Dermatologists need to be aware of the serious adverse reactions that can develop after minocycline use. In patients who may require long-term therapy with minocycline ( > 1 year), we suggest that antinuclear antibody and hepatic transaminase levels be determined at baseline. Rechallenge with minocycline or other tetracyclines is currently not recommended for patients who develop these serious reactions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8712844

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  14 in total

Review 1.  Reactive metabolites and adverse drug reactions: clinical considerations.

Authors:  Sandra R Knowles; Lori E Shapiro; Neil H Shear
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

2.  Minocycline toxicity requiring liver transplant.

Authors:  Julian E Losanoff; Jennifer M Holder-Murray; Emily B Ahmed; Adam B Cochrane; Giuliano Testa; J Michael Millis
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

3.  A case of anaphylaxis to oral minocycline.

Authors:  Ji Woong Jang; Yun-Jeong Bae; Yong Giun Kim; Young-Joo Jin; Kyung Sun Park; You Sook Cho; Hee-Bom Moon; Tae-Bum Kim
Journal:  J Korean Med Sci       Date:  2010-07-21       Impact factor: 2.153

Review 4.  Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.

Authors:  S R Knowles; L E Shapiro; N H Shear
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

5.  Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data.

Authors:  R A Lawrenson; H E Seaman; A Sundström; T J Williams; R D Farmer
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

Review 6.  Minocycline for acne vulgaris: efficacy and safety.

Authors:  Sarah E Garner; Anne Eady; Cathy Bennett; John Norman Newton; Karen Thomas; Catalin Mihai Popescu
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

7.  Safety of celecoxib in individuals allergic to sulfonamide: a pilot study.

Authors:  Lori E Shapiro; Sandra R Knowles; Elizabeth Weber; Manuela G Neuman; Neil H Shear
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Minocycline-induced hypersensitivity syndrome presenting with meningitis and brain edema: a case report.

Authors:  Nicolas Lefebvre; Emmanuel Forestier; David Farhi; Mohseni Zadeh Mahsa; Véronique Remy; Olivier Lesens; Daniel Christmann; Yves Hansmann
Journal:  J Med Case Rep       Date:  2007-05-18

Review 9.  Structural determinants of antibiotic allergy.

Authors:  B A Baldo; Z Zhao; N H Pham
Journal:  Curr Allergy Rep       Date:  2001-01

Review 10.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.